Bioorganic & Medicinal Chemistry · 2011 · 49 citations · 37 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryPharmacophore ModelingPharmacophore Hypothesis GenerationPharmacophore ScreeningPharmacophore ValidationPharmacophore-based Lead DiscoveryStructure-activity Relationship AnalysisStructure-based Pharmacophore ModelingFarnesoid X Receptor AgonistsLipid Metabolism RegulationPharmacophore Hypothesis ValidationPharmacophore Model ConstructionPharmacophore-based Database ScreeningStructure-activity Relationship ModelingStructure-based Pharmacophore DesignStructure-based Pharmacophore Generation
The farnesoid X receptor (FXR) is involved in glucose and lipid metabolism regulation, which makes it an attractive target for the metabolic syndrome, dyslipidemia, atherosclerosis, and type 2 diabetes. In order to find novel FXR agonists, a structure-based pharmacophore model collection was developed and theoretically evaluated against virtual databases including the ChEMBL database. The most suitable models were used to screen the National Cancer Institute (NCI) database. Biological evaluation of virtual hits led to the discovery of a novel FXR agonist with a piperazine scaffold (compound 19) that shows comparable activity as the endogenous FXR agonist chenodeoxycholic acid (CDCA, compound 2).
37
Improved protein–ligand docking using GOLD
Marcel L. Verdonk, Jason C. Cole, Michael J. Hartshorn et al. · Proteins Structure Function and Bioinformatics · 2003 · 3K citations · Full text
DrugBank: a knowledgebase for drugs, drug actions and drug targets
David S. Wishart, Craig Knox, An Chi Guo et al. · Nucleic Acids Research · 2007 · 2.9K citations · Full text
Identification of a Nuclear Receptor for Bile Acids
Makoto Makishima, Arthur Y. Okamoto, Joyce J. Repa et al. · Science · 1999 · 2.7K citations